Please verify your email address. Naruto features a wide variety of well-crafted and powerful female characters that have unique designs and fascinating stories. Despite being overshadowed by male ...

H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases. The Danish pharmaceutical company is offering ...

Longboard Pharmaceuticals (LBPH) on Monday agreed to be acquired by Danish pharmaceutical company H. Lundbeck in a deal with an equity value of about $2.6 billion. Lundbeck will launch a tender ...

As you can see below, the sneak peek was posted by ANN ahead of the comic’s debut next week. Teenage Mutant Ninja Turtles x Naruto is set to begin in mid-November.The special preview brings Team ...

H. Lundbeck A/S will acquire Longboard Pharmaceuticals for $60 per share in a $2.6 billion deal, closing in Q4 2024. Longboard’s lead asset, bexicaserin, is under development for neurological ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

Shares of Longboard Pharmaceuticals, Inc. LBPH rose sharply in today's pre-market trading. Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

LONDON — The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals, which is developing treatments for neurological diseases, in a deal worth $2.6 billion.

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment.